Proqr Therapeutics, Leiden Videos

ProQR's Axiomer technology explained - What is Axiomer?
In celebration of the 4th RNA Editing Summit in Boston check out our new video. What is Axiomer®? Find the full series of videos on our website: https://bit.ly/3NNmv9o or YouTube page: https://youtu.be/2KmGkQF24cQ

How does RNA editing work
Interested to learn more about RNA editing? Check out our short video below!

PROQR_Trailer_Subtitles.mp4
Today is #WorldSightDay! In this interview Morten explains his extraordinary take on life with a #VisualImpairment and how he came to view it as a blessing. Morten lives with retinitis pigmentosa and visited Leiden with his wife Mette for a tour around our labs and a meet and greet with Maarten, one of ProQR’s scientists that works on RNA therapies for genetic eye diseases. Watch the full video here: https://www.youtube.com/watch?v=tM-lNtwo9g8 #BlindnessAwarenessMonth

ProQR's CEO Daniel de Boer talks about his personal journey with #RareDisease and motivations for starting a company dedicated to changing lives through innovative medicines. #RareDiseaseDay #Retina #Ophthalmology

Rare Disease Day 2021 - Scientist Marko explains how working in rare diseases gives meaning to his life.
Our scientists are as strongly committed today as they were at our founding in 2012. Our Associate Scientist Marko outlines what inspires him to work in rare disease. #RareDiseaseDay #InheritedRetinalDisease

An RNA therapy differs from gene therapy and CRISPR because it doesn't change your DNA. Learn about the role RNA plays in causing and potentially treating genetic diseases like Leber congenital amaurosis and retinitis pigmentosa: https://www.proqr.com/RNA-therapy An RNA therapy is designed to correct the mistake, or mutation, in the RNA of someone with a genetic disease. By correcting the mistake, the RNA can then be used to create the protein that the cell needs, taking away the underlying cause of the disease. ProQR is at the forefront of delivering precision medicine for people with inherited retinal diseases. Our RNA therapies use antisense oligonucleotides which are specifically designed to correct the underlying cause of the disease in a person’s RNA to stop disease progression or even reverse symptoms.

Pr. Stephen Russell from @uiowaeye and @benshaberman from @fightblindness discuss data from our Phase 1/2 clinical trial of sepofarsen, an RNA therapy for Leber congenital amaurosis. Access the full video here: https://bit.ly/2UTKtoJ #VisuallyImpaired #PartiallySighted #Blind #Blindness #Retina #LowVision #EyeHealth

Trailer ProQR talk episode 1: 'Accessible information in an isolated time'

ProQR Rare Disease Day

ProQR's Promise